Clinical Trial Update: PREVACT : Preventive REversal of Vitamine K Antagonist in Minor Craniocerebral Trauma [Phase 3]

View source ↗

Summary

Phase 3 trial PREVACT on reversal of vitamin K antagonist in minor craniocerebral trauma was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Craniocerebral Trauma
• Haemorrhage

Drugs mentioned

• PREVACT

Snippet

Sponsor: University Hospital, Angers | Conditions: Coagulation; Intravascular, Craniocerebral Trauma | Phase 3 | Status: TERMINATED